Neuroleptic malignant syndrome: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
m (Typo)
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Neuroleptic malignant sydrome''' is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see [[antipsychotic agent]]s) which are in turn associated with [[Biogenic amine receptor|dopaminergic receptor]] blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; [[tremor]]; high [[fever]]; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."<ref>{{MeSH}}</ref><ref name="isbn0-07-067439-6">{{cite book |author=Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice |title=Principles of Neurology |publisher=McGraw-Hill, Health Professions Division |location=New York |year=1997 |pages=1199 |isbn=0-07-067439-6 |oclc= |doi=}}</ref><ref name="pmid9735957">{{cite journal |author=Pelonero AL, Levenson JL, Pandurangi AK |title=Neuroleptic malignant syndrome: a review |journal=Psychiatr Serv |volume=49 |issue=9 |pages=1163-72 |year=1998 |pmid=9735957 |doi= |url=http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=9735957}}</ref>
'''Neuroleptic malignant syndrome''' is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see [[antipsychotic agent]]s) which are in turn associated with [[Biogenic amine receptor|dopaminergic receptor]] blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; [[tremor]]; high [[fever]]; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."<ref>{{MeSH}}</ref><ref name="isbn0-07-067439-6">{{cite book |author=Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice |title=Principles of Neurology |publisher=McGraw-Hill, Health Professions Division |location=New York |year=1997 |pages=1199 |isbn=0-07-067439-6 |oclc= |doi=}}</ref><ref name="pmid9735957">{{cite journal |author=Pelonero AL, Levenson JL, Pandurangi AK |title=Neuroleptic malignant syndrome: a review |journal=Psychiatr Serv |volume=49 |issue=9 |pages=1163-72 |year=1998 |pmid=9735957 |doi= |url=http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=9735957}}</ref>


==References==
==References==

Revision as of 06:45, 2 April 2008

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Neuroleptic malignant syndrome is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see antipsychotic agents) which are in turn associated with dopaminergic receptor blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; tremor; high fever; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."[1][2][3]

References

  1. Anonymous (2024), Neuroleptic malignant syndrome (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice (1997). Principles of Neurology. New York: McGraw-Hill, Health Professions Division, 1199. ISBN 0-07-067439-6. 
  3. Pelonero AL, Levenson JL, Pandurangi AK (1998). "Neuroleptic malignant syndrome: a review". Psychiatr Serv 49 (9): 1163-72. PMID 9735957[e]

See also